Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study by Sevinj Yolchuyeva, PhD, Elena Giacomazzi, MSc, Marion Tonneau, PhD, Fabien Lamaze, PhD, Michele Orain, MT, François Coulombe, MD, Julie Malo, CCRP, Wiam Belkaid, PhD, Bertrand Routy, MD, PhD, Philippe Joubert, MD, PhD, Venkata S.K. Manem, MSc, PhD

Get full text